MICHELLE DAVIS: Open Payments
NPI 1568075604 · SALT LAKE CITY, UT. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,931 in 66 payments from 16 companies in 2025. Trend: 2023 $650 · 2024 $1,231 · 2025 $1,931
Food & beverage: $1,889Education: $42
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 11 | $427 |
| Regeneron Healthcare Solutions, Inc. | 9 | $349 |
| GlaxoSmithKline, LLC. | 9 | $298 |
| GENZYME CORPORATION | 13 | $215 |
| Genentech USA, Inc. | 2 | $142 |
| Organon LLC | 3 | $138 |
| Amgen Inc. | 3 | $75 |
| Novartis Pharmaceuticals Corporation | 4 | $71 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $54 |
| BioCryst US Sales Co., LLC | 2 | $37 |
Products named: DUPIXENT, AIRSUPRA, NUCALA, Xolair, VTAMA, TEZSPIRE, FASENRA, ORLADEYO.
Industry payments across UT — which companies pay providers there.
